Specifically, a few studies have reported that NAFLD is associated with decreased expression and function of CYP3A4, a major member of the hepatic cytochrome P450 superfamily contributing to the metabolism of 45–60% of all drugs used in the clinical setting (Wojnowski and Kamdem, 2006; Anglicheau et al., 2007). The gene discussed is CYP3A4; the disease is metabolic dysfunction-associated steatotic liver disease.